Fluticasone propionate/salmeterol (Advair HFA) vs indacaterol maleate / mometasone furoate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
indacaterol maleate / mometasone furoate
Marketed by Novartis
NCT00557440 · Phase 2 · completed
The study was randomized and quadruple-blind, used both placebo and active control, and measured the clinically relevant lung-function endpoint FEV1. Although the primary comparison favored indacaterol/mometasone over placebo and was statistically significant, the small sample of 37 participants limits the strength of the evidence.
Next expected readout: February 2028 · NCT05562466 (registry estimate)
Reported efficacy
Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016) (met)
Result source: NCT02554786
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Fluticasone propionate/salmeterol (Advair HFA) | indacaterol maleate / mometasone furoate |
|---|---|---|
| Severe exacerbations, annualised rate | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 | —Trial running · NCT05562466 |
| Trough FEV1, change | —Not posted · NCT00646620 | 0.1 vs -0.1+0.2 vs placeboNCT00557440 |
| ACQ-5, change | —Not posted · NCT00646620 | —Trial running · NCT05562466 |
| OCS dose reduction | —Not posted · NCT00646620 | —Trial running · NCT05562466 |
Severe exacerbations, annualised rate
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
- indacaterol maleate / mometasone furoate
- —Trial running · NCT05562466
Trough FEV1, change
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- indacaterol maleate / mometasone furoate
- 0.1 vs -0.1+0.2 vs placeboNCT00557440
ACQ-5, change
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- indacaterol maleate / mometasone furoate
- —Trial running · NCT05562466
OCS dose reduction
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- indacaterol maleate / mometasone furoate
- —Trial running · NCT05562466
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fluticasone propionate/salmeterol (Advair HFA): 4 of 4 rows · indacaterol maleate / mometasone furoate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone propionate/salmeterol (Advair HFA) | indacaterol maleate / mometasone furoate |
|---|---|---|
| Dropout rate | —50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence | — NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more result0% NCT00605306 · Phase 2 · Asthma · phase 2 |
| Discontinued due to AEs | —50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence | — NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more result0% NCT00605306 · Phase 2 · Asthma · phase 2 |
| Serious AEs | 0%50/100 mcg/daya NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence | 0% NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more result0% NCT00605306 · Phase 2 · Asthma · phase 2 |
| Most frequent reported AEs | 50/100 mcg/daya upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence | headache 5.6% (placebo 5.4%) NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more resultcough 35.7% (placebo 14.3%) headache 35.7% (placebo 14.3%) bronchitis 14.3% (placebo 0%) NCT00605306 · Phase 2 · Asthma · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone propionate/salmeterol (Advair HFA)
+ 12 further endpoints in the CSV export.
indacaterol maleate / mometasone furoate
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · indacaterol maleate / mometasone furoate's landscape